News Enanta weakens on RSV treatment trial readout Shares in Enanta Pharma were sliding this morning after it reported results of a phase 2b trial of its RSV antiviral zelicapavir.
News Enanta lawsuit claims Pfizer's Paxlovid infringes its patent US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
